Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis.
Pharmacokinetics of CAMPATH-1H in BMT patients.
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations
Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies.
Change in the clinical development program for laquinimod
Normal Appearing and Diffusely Abnormal White Matter in Patients with Multiple Sclerosis Assessed with Quantitative MR.
The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple scl
Intermittent self-catheterisation in MS.
Recent advances in the drug discovery of metabotropic glutamate receptor 4 (mGluR4) activators for the treatment of CNS and non-CNS disorders.
Teva announces top-line results from GALA Phase III trial evaluating a new dosage for glatiramer acetate given three times weekly for relapsing-remitting multiple sclerosis
Genzyme presents second Phase III study of once-daily oral AUBAGIO® (teriflunomide) confirming significant impact on disability
Patient reported outcome measures in neurogenic bladder.
The Relative Importance of Baseline Pain, Fatigue, Sleep and Physical Activity: Predicting Change in Depression in Adults with Multiple Sclerosis.
The Effect of Glatiramer Acetate Therapy on Functional Properties of B Cells From Patients With Relapsing-Remitting Multiple Sclerosis.
Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review.
Small internal jugular veins with restricted outflow are associated with severe multiple sclerosis: a sonographer-blinded, case--control ultrasound study.
Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome.
Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine.
Glatiramer acetate in the treatment of multiple sclerosis
Biogen Idec completes purchase of full rights and control of Tysabri®
The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis.
Genzyme’s LEMTRADA™ (alemtuzumab) application for MS accepted for review by the FDA
American Academy of Neurology Annual Meeting
The interplay between the intestinal microbiota and the brain.
Cortical demyelination and diffuse white matter injury in multiple sclerosis.

Pages